Finance Technology Director

WEX introduces specialized HRA. - March 27, 2026 Why it matters. Employers gain fiscal predictability and employee access to high-cost weight-loss drugs, addressing a growing benefits challenge as GLP-1 usage expands across the workforce. Key takeaways. * - 34 million Americans qualify for GLP-1 drugs * - Employers face rising premiums for weight-loss medications * - WEX HRA caps costs via defined contributions * - Flexible reimbursement covers pharmacies and manufacturer programs * - Solution reduces admin burden for HR teams Summary. WEX Inc. launched a specialized Health Reimbursement Arrangement (HRA) to help employers manage the soaring costs of GLP-1 medications, which are now used by an estimated 34 million Americans for weight management. The solution lets companies allocate a fixed contribution for GLP-1 coverage, giving employees access across pharmacies and manufacturer programs while shielding core medical plans from premium inflation. By customizing funding and reimbursement rules, the HRA provides predictable budgeting and reduces administrative burdens for HR teams. The offering is immediately available to employers, brokers, and consultants seeking a modern benefit strategy. Pulse analysis. The rapid uptake of GLP-1 agonists, originally diabetes treatments now popular for weight management, has reshaped the U.S. benefits landscape. With roughly 34 million Americans meeting clinical criteria, demand outpaces traditional pharmacy budgets, driving premium spikes that strain employer-sponsored health plans. Companies with 200+ employees report that nearly one-in-five already cover these drugs, forcing a choice between absorbing cost inflation or eliminating coverage altogether. This tension highlights a broader shift toward high-cost specialty medicines that challenge conventional benefit design. WEX's new Health Reimbursement Arrangement tackles the dilemma by converting GLP-1 coverage into a defined-contribution model. Employers allocate a fixed dollar amount per participant, which employees can draw for prescriptions at any pharmacy, manufacturer-direct program, or alternative channel. The platform's payment rails enforce eligibility rules in real time, ensuring spend stays within budget while preserving employee access. By moving from open-ended liability to predictable funding, HR leaders gain fiscal clarity, reduce administrative overhead, and can align drug benefits with broader wellness strategies. The introduction of a specialized HRA signals a maturation of benefits administration toward more granular, data-driven solutions. As other specialty drugs follow the GLP-1 trajectory, PULSE can expect similar contribution-based models to proliferate, giving employers greater control over escalating pharma costs. For WEX, the offering expands its portfolio beyond payment processing into strategic benefits consulting, positioning the firm as a one-stop shop for intelligent benefit design. Ultimately, employees benefit from sustained access to clinically valuable therapies without exposing employers to unsustainable premium growth. HRTech Cube Strategic HRA offering unlocks predictable, sustainable costs for employers, all while granting access to meaningful, in-demand medication for employees WEX Inc. (NYSE: WEX), a global leader in intelligence-led payment and workflow solutions, today announced the launch of a Health Reimbursement Arrangement (HRA) designed to help employers manage the surging demand and escalating costs of GLP-1 medications. WEX's specialized solution enables organizations to carve out GLP-1 coverage into a defined-contribution HRA. This puts the power back to the employer amidst shifting economic conditions by helping protect the organization's core medical plan from unpredictable utilization and premium inflation. By customizing everything from funding to reimbursement rules, employers gain clarity and control over pricing, while ensuring their employees have a reliable safety net for their health journeys. Once considered a niche treatment for diabetes, GLP-1 medications are now demanding a shift in how employers approach holistic health and wellness in the workplace, as nearly 34 million Americans now medically qualify for these weight-management drugs. While research shows that one-in-five (19 %) organizations with 200 + workers covered GLP-1 drugs in 2025, the explosion in popularity has created a fiscal dilemma for many on the fence: absorb skyrocketing premiums to cover the medications or cut them entirely. "With this new HRA offering from WEX, we tackle one of the most complex challenges in the healthcare ecosystem: How to balance fiscal sustainability and employee well-being amidst skyrocketing drug costs," said Robert Deshaies, Chief Operating Officer, Benefits at WEX. "By helping to reduce risk for the employer through this defined-contribution model, we enable organizations to provide easier access for employees to manage their physical health as well as their financial health." Precision control, for meaningful access. By leveraging proven HRA infrastructure and reimbursement capabilities, WEX enables plan sponsors to shift away from open-ended benefit exposure toward a model where GLP-1 access is offered with clear funding parameters and controlled costs. Key features and benefits of this new solution include: * Flexible Access for Employees: Instead of navigating high out-of-pocket costs alone, funds can be utilized across pharmacies, manufacturer-direct programs, or alternative channels. * Strategic Advantage for Employers: By combining scale and compliance expertise into a single, intelligent engine, WEX is able to power the full spectrum of benefits and payments across one secure infrastructure. Without the burden of manual administration, HR teams gain peace of mind and the ability to remain focused on high-level strategy. * WEX Payment Rails: Utilizing WEX's proprietary technology, the HRA offering ensures that every dollar spent is aligned with the employer's specific eligibility rules, while providing a seamless reimbursement experience. The WEX GLP-1 HRA is available now for employers, partners, brokers, and consultants looking to modernize their weight-management benefit strategy. Want to join the conversation?

WEX (NYSE: WEX) files proxy; board urges vote for its nine nominees amid Impactive challenge. Filing Impact Filing Sentiment Rhea-AI filing summary. WEX Inc. filed a preliminary proxy statement dated March 24, 2026 for its virtual 2026 Annual Meeting, asking stockholders to elect nine directors, approve an advisory vote on executive compensation, and ratify Deloitte & Touche as auditor. The Board recommends voting "FOR" only the nine Company nominees and urges use of the enclosed universal BLUE proxy card. The filing discloses a contested solicitation by Impactive Capital (which has nominated four directors) and summarizes multi-year engagement, Board refreshment actions, and prior capital return programs including share repurchase authorizations and an ASR that repurchased $300 million (1,517,580 shares). The filing notes potential bank regulatory filings that may affect Impactive's solicitation. Insights. Proxy contest frames as governance and succession dispute, not a regulatory ruling. The filing details a multi-year engagement between the Board and Impactive culminating in a contested election and the use of a universal proxy card. The Board reduced seats from 12 to 9 and nominated nine Company directors while describing ongoing refreshment efforts and independent committee oversight. Key items to watch in subsequent filings include final vote tallies filed on Form 8-K and any regulatory applications referenced by the FDIC and UDFI; timing and voting results will determine board composition and near-term governance outcomes. Capital return history is central to the shareholder dialogue. The proxy recounts extensive buyback activity including authorizations of $150 million, $650 million, an expanded program to $1.05 billion, and later to $2.05 billion, plus an $300 million ASR that repurchased 1,517,580 shares. These actions are repeatedly cited in engagement with Impactive. Future disclosures to track: final vote results, any agreed changes to capital allocation or strategic divestitures, and whether bank regulators require filings that could affect Impactive's proxy votes. 03/24/2026 - 04:30 PM Faq. What is WEX (WEX) asking shareholders to vote on at the 2026 Annual Meeting? WEX asks shareholders to elect nine directors, approve an advisory vote on Named Executive Officer compensation, and ratify Deloitte & Touche LLP as auditor. The Board recommends voting "FOR" only the nine Company nominees using the universal BLUE proxy card. Who are the dissident nominees and how does Impactive factor into the proxy contest? Impactive Capital notified WEX it intends to nominate four directors and has circulated a universal white proxy card. The Company describes multi-year engagement with Impactive and urges shareholders to use the BLUE card and vote for the nine Company nominees. How has WEX recently used share repurchases and what repurchase programs are disclosed? WEX disclosed multiple repurchase authorizations including $150 million, $650 million, expansions to $1.05 billion and $2.05 billion, and an ASR of $300 million that repurchased 1,517,580 shares, as described in the proxy timeline. Will the universal proxy card list both Company and Impactive nominees? Yes. Under SEC universal proxy rules, both the Company's nominees and Impactive's nominees will appear on each proxy card. Stockholders may vote for nominees from either slate but may not vote for more nominees than seats available. Could Impactive's proxy votes be invalidated by bank regulator requirements? The filing states the FDIC and Utah Department of Financial Institutions notified Impactive it may need to submit applications in connection with its solicitation; the proxy notes failure to file and obtain approval could invalidate votes obtained by Impactive.